New prestigious grants support Lario's unique portfolio of calcium channel programmes -- Indication expansion into Parkinson's disease, and PTSD (post-traumatic stress disorders) -- Builds on prior ...

Funding from MJFF and Wellcome supports expansion into Parkinson’s and PTSD Lario Therapeutics has secured $2.4 million in new grant funding from The Michael J Fox Foundation for Parkinson’s Research ...

New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

Myotonic dystrophy is one of the most common forms of muscular dystrophy. It is a genetic condition that causes progressive muscle weakness and wasting. No treatments currently exist that slow the ...

Researchers at the University Medical Center Göttingen (UMG) have shown how a minimal change in a single ion channel increases the sensitivity of sensory cells in the inner ear. Even soft sounds, such ...

New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

Examining data on more than 400,000 participants in the U.K. Biobank revealed that use of CCBs was associated with a 39% greater odds of glaucoma after adjusting for various factors, including the use ...

New York University (NYU) researchers suggest that ORAI1 calcium channel activity in oral cancer cells could be targeted to reduce the growth of oral tumors and reduce pain, according to a study that ...

Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor. ET is a ...

In a recent study posted to the bioRxiv* preprint server, researchers investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope (E) protein activity in terms of calcium ...